{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:10:04Z","timestamp":1791609004073,"version":"4.3.4"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40272-021-00477-9","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T13:05:24Z","timestamp":1634907924000},"page":"29-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Medical Management of Infantile Hemangiomas: An Update"],"prefix":"10.1007","volume":"24","author":[{"given":"Caroline","family":"Colmant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7330-496X","authenticated-orcid":false,"given":"Julie","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"4","key":"477_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/bjd.12804","volume":"170","author":"A Munden","year":"2014","unstructured":"Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170(4):907\u201313. https:\/\/doi.org\/10.1111\/bjd.12804.","journal-title":"Br J Dermatol"},{"issue":"10089","key":"477_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0140-6736(16)00645-0","volume":"390","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(16)00645-0.","journal-title":"Lancet"},{"key":"477_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3475","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2018-3475.","journal-title":"Pediatrics"},{"issue":"12","key":"477_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/ddg.13365","volume":"15","author":"A Rotter","year":"2017","unstructured":"Rotter A, de Oliveira ZNP. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Dtsch Dermatol Ges. 2017;15(12):1185\u201390. https:\/\/doi.org\/10.1111\/ddg.13365.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"477_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/bjd.13388","volume":"172","author":"Y Ji","year":"2015","unstructured":"Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172(1):24\u201332. https:\/\/doi.org\/10.1111\/bjd.13388.","journal-title":"Br J Dermatol"},{"issue":"2","key":"477_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.pcl.2018.12.011","volume":"66","author":"N Harter","year":"2019","unstructured":"Harter N, Mancini AJ. Diagnosis and management of infantile hemangiomas in the neonate. Pediatr Clin N Am. 2019;66(2):437\u201359. https:\/\/doi.org\/10.1016\/j.pcl.2018.12.011.","journal-title":"Pediatr Clin N Am"},{"issue":"4","key":"477_CR7","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/PRS.0b013e318208d2ac","volume":"127","author":"CG Bauland","year":"2011","unstructured":"Bauland CG, L\u00fcning TH, Smit JM, Zeebregts CJ, Spauwen PHM. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg. 2011;127(4):1643\u20138. https:\/\/doi.org\/10.1097\/PRS.0b013e318208d2ac.","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"477_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1542\/peds.2007-2767","volume":"122","author":"LC Chang","year":"2008","unstructured":"Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360\u20137. https:\/\/doi.org\/10.1542\/peds.2007-2767.","journal-title":"Pediatrics"},{"issue":"2","key":"477_CR9","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1542\/peds.2011-3683","volume":"130","author":"MM Tollefson","year":"2012","unstructured":"Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents\u2019 photographs tell us. Pediatrics. 2012;130(2):e314\u201320. https:\/\/doi.org\/10.1542\/peds.2011-3683.","journal-title":"Pediatrics"},{"issue":"11","key":"477_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jamadermatol.2016.2905","volume":"152","author":"E Baselga","year":"2016","unstructured":"Baselga E, Roe E, Coulie J, Mu\u00f1oz FZ, Boon LM, McCuaig C, et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol. 2016;152(11):1239\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2905.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"477_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PRS.0b013e31825dc129","volume":"130","author":"RA Couto","year":"2012","unstructured":"Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg. 2012;130(3):619\u201324. https:\/\/doi.org\/10.1097\/PRS.0b013e31825dc129.","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"477_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1542\/peds.2015-2482","volume":"136","author":"DH Darrow","year":"2015","unstructured":"Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and management of infantile hemangioma: executive summary. Pediatrics. 2015;136(4):786\u201391. https:\/\/doi.org\/10.1542\/peds.2015-2482.","journal-title":"Pediatrics"},{"issue":"2","key":"477_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jaad.2018.07.061","volume":"80","author":"KF O'Brien","year":"2019","unstructured":"O\u2019Brien KF, Shah SD, Pope E, Phillips RJ, Blei F, Baselga E, et al. Late growth of infantile hemangiomas in children > 3 years of age: a retrospective study. J Am Acad Dermatol. 2019;80(2):493\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.061.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"477_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000107633","volume":"215","author":"B Drolet","year":"2007","unstructured":"Drolet B, Garzon M. SACRAL syndrome. Dermatology. 2007;215(4):360. https:\/\/doi.org\/10.1159\/000107633 (Author reply-1).","journal-title":"Dermatology"},{"issue":"7","key":"477_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/archderm.142.7.884","volume":"142","author":"C Girard","year":"2006","unstructured":"Girard C, Bigorre M, Guillot B, Bessis D. PELVIS syndrome. Arch Dermatol. 2006;142(7):884\u20138. https:\/\/doi.org\/10.1001\/archderm.142.7.884.","journal-title":"Arch Dermatol"},{"issue":"5","key":"477_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.otc.2008.04.009","volume":"41","author":"TO Lee","year":"2008","unstructured":"Lee TO, Messner A. Subglottic hemangioma. Otolaryngol Clin N Am. 2008;41(5):903\u201311. https:\/\/doi.org\/10.1016\/j.otc.2008.04.009.","journal-title":"Otolaryngol Clin N Am"},{"issue":"5","key":"477_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jaad.2020.11.062","volume":"84","author":"Y Ji","year":"2020","unstructured":"Ji Y, Chen S, Yang K, Xiang B, Jiang X, Xu X, et al. Screening for infantile hepatic hemangioma in patients with cutaneous infantile hemangioma: a multicenter prospective study. J Am Acad Dermatol. 2020;84(5):1378\u201384. https:\/\/doi.org\/10.1016\/j.jaad.2020.11.062.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"477_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1684\/ejd.2008.0576","volume":"19","author":"DJ Hermans","year":"2009","unstructured":"Hermans DJ, Boezeman JB, Van de Kerkhof PC, Rieu PN, Van der Vleuten CJ. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur J Dermatol. 2009;19(2):152\u20136. https:\/\/doi.org\/10.1684\/ejd.2008.0576.","journal-title":"Eur J Dermatol"},{"key":"477_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0469","author":"E Fern\u00e1ndez Faith","year":"2021","unstructured":"Fern\u00e1ndez Faith E, Shah S, Witman PM, Harfmann K, Bradley F, Blei F, et al. Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma. JAMA Dermatol. 2021. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0469.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"477_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s002470050718","volume":"29","author":"J Dubois","year":"1999","unstructured":"Dubois J, Garel L. Imaging and therapeutic approach of hemangiomas and vascular malformations in the pediatric age group. Pediatr Radiol. 1999;29(12):879\u201393. https:\/\/doi.org\/10.1007\/s002470050718.","journal-title":"Pediatr Radiol"},{"key":"477_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jpeds.2018.08.012","volume":"203","author":"I Iacobas","year":"2018","unstructured":"Iacobas I, Phung TL, Adams DM, Trenor CC 3rd, Blei F, Fishman DS, et al. Guidance document for hepatic hemangioma (infantile and congenital) evaluation and monitoring. J Pediatr. 2018;203:294-300.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2018.08.012.","journal-title":"J Pediatr"},{"issue":"2","key":"477_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.19472","volume":"184","author":"C Mahon","year":"2021","unstructured":"Mahon C, McHugh K, Alband N, Rampling D, Sebire N, Williamson E, et al. Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma. Br J Dermatol. 2021;184(2):340\u20131. https:\/\/doi.org\/10.1111\/bjd.19472.","journal-title":"Br J Dermatol"},{"issue":"3","key":"477_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/bjd.16779","volume":"179","author":"L Solman","year":"2018","unstructured":"Solman L, Glover M, Beattie PE, Buckley H, Clark S, Gach JE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179(3):582\u20139. https:\/\/doi.org\/10.1111\/bjd.16779.","journal-title":"Br J Dermatol"},{"key":"477_CR24","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1628","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2020","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Baselga Torres E, Weibel L, Boon LM, El Hachem M, van der Vleuten C, et al. The infantile hemangioma referral score: a validated tool for physicians. Pediatrics. 2020. https:\/\/doi.org\/10.1542\/peds.2019-1628.","journal-title":"Pediatrics"},{"issue":"24","key":"477_CR25","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","volume":"358","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Hubiche T, Boralevi F, Thambo JB, Ta\u00efeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649\u201351. https:\/\/doi.org\/10.1056\/NEJMc0708819.","journal-title":"N Engl J Med"},{"issue":"8","key":"477_CR26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","volume":"372","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1404710.","journal-title":"N Engl J Med"},{"issue":"1","key":"477_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjd.12217","volume":"169","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2013","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, de la Roque ED, Nacka F, Abouelfath A, Grenier N, Rebola M, et al. Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age. Br J Dermatol. 2013;169(1):181\u20133. https:\/\/doi.org\/10.1111\/bjd.12217.","journal-title":"Br J Dermatol"},{"issue":"2","key":"477_CR28","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1542\/peds.2010-0029","volume":"128","author":"M Hogeling","year":"2011","unstructured":"Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128(2):e259\u201366. https:\/\/doi.org\/10.1542\/peds.2010-0029.","journal-title":"Pediatrics"},{"issue":"2","key":"477_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/pde.12089","volume":"30","author":"AL Marqueling","year":"2013","unstructured":"Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30(2):182\u201391. https:\/\/doi.org\/10.1111\/pde.12089.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"477_CR30","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/bjd.12432","volume":"169","author":"CK Ahogo","year":"2013","unstructured":"Ahogo CK, Ezzedine K, Prey S, Colona V, Diallo A, Boralevi F, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol. 2013;169(6):1252\u20136. https:\/\/doi.org\/10.1111\/bjd.12432.","journal-title":"Br J Dermatol"},{"issue":"6","key":"477_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2017.0250","volume":"153","author":"KH Kim","year":"2017","unstructured":"Kim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, et al. Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. JAMA Dermatol. 2017;153(6):529\u201336. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0250.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"477_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13331","volume":"33","author":"K Kridin","year":"2020","unstructured":"Kridin K, Pam N, Bergman R, Khamaysi Z. Oral propranolol administration is effective for infantile hemangioma in late infancy: a retrospective cohort study. Dermatol Ther. 2020;33(3): e13331. https:\/\/doi.org\/10.1111\/dth.13331.","journal-title":"Dermatol Ther"},{"issue":"3","key":"477_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bjd.14233","volume":"174","author":"E Wedgeworth","year":"2016","unstructured":"Wedgeworth E, Glover M, Irvine AD, Neri I, Baselga E, Clayton TH, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European propranolol in the treatment of complicated haemangiomas (PITCH) taskforce survey. Br J Dermatol. 2016;174(3):594\u2013601. https:\/\/doi.org\/10.1111\/bjd.14233.","journal-title":"Br J Dermatol"},{"issue":"1","key":"477_CR34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1542\/peds.2012-1691","volume":"131","author":"BA Drolet","year":"2013","unstructured":"Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128\u201340. https:\/\/doi.org\/10.1542\/peds.2012-1691.","journal-title":"Pediatrics"},{"issue":"2","key":"477_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1001\/jamadermatol.2019.3839","volume":"156","author":"GM Olsen","year":"2020","unstructured":"Olsen GM, Hansen LM, Stefanko NS, Mathes E, Puttgen KB, Tollefson MM, et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol. 2020;156(2):186\u201390. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3839.","journal-title":"JAMA Dermatol"},{"key":"477_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.013","author":"KB P\u00fcttgen","year":"2020","unstructured":"P\u00fcttgen KB, Hansen LM, Lauren C, Stefanko N, Mathes E, Olsen GM, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2020. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.013.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"477_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13977","volume":"33","author":"A Bassi","year":"2020","unstructured":"Bassi A, Azzarelli A, Vaccaro A, Mazzatenta C. At-home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic. Dermatol Ther. 2020;33(6): e13977. https:\/\/doi.org\/10.1111\/dth.13977.","journal-title":"Dermatol Ther"},{"key":"477_CR38","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-3866","author":"E Baselga","year":"2018","unstructured":"Baselga E, Dembowska-Baginska B, Przewratil P, Gonz\u00e1lez-Ense\u00f1at MA, Wyrzykowski D, Torrelo A, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018. https:\/\/doi.org\/10.1542\/peds.2017-3866.","journal-title":"Pediatrics"},{"key":"477_CR39","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1754","author":"SD Shah","year":"2016","unstructured":"Shah SD, Baselga E, McCuaig C, Pope E, Coulie J, Boon LM, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2015-1754.","journal-title":"Pediatrics"},{"issue":"2","key":"477_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00431-020-03872-5","volume":"180","author":"G Frongia","year":"2021","unstructured":"Frongia G, Byeon JO, Mehrabi A, G\u00fcnther P. Recurrence rate of infantile hemangioma after oral propranolol therapy. Eur J Pediatr. 2021;180(2):585\u201390. https:\/\/doi.org\/10.1007\/s00431-020-03872-5.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"477_CR41","doi-asserted-by":"publisher","first-page":"586","DOI":"10.5863\/1551-6776-25.7.586","volume":"25","author":"L Tiemann","year":"2020","unstructured":"Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther. 2020;25(7):586\u201399. https:\/\/doi.org\/10.5863\/1551-6776-25.7.586.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"477_CR42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jdcr.2020.01.028","volume":"6","author":"H Al-Rwebah","year":"2020","unstructured":"Al-Rwebah H, Alkhodair R, Al-Khenaizan S. Propranolol-induced hyperkalemia in the management of infantile hemangioma. JAAD Case Rep. 2020;6(4):359\u201361. https:\/\/doi.org\/10.1016\/j.jdcr.2020.01.028.","journal-title":"JAAD Case Rep."},{"issue":"2","key":"477_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000337553","volume":"224","author":"R Cavalli","year":"2012","unstructured":"Cavalli R, Buffon RB, de Souza M, Colli AM, Gelmetti C. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? Dermatology. 2012;224(2):106\u20139. https:\/\/doi.org\/10.1159\/000337553.","journal-title":"Dermatology"},{"key":"477_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-203746","author":"B Belen","year":"2014","unstructured":"Belen B, Oguz A, Okur A, Dalgic B. A complication to be aware of: hyperkalaemia following propranolol therapy for an infant with intestinal haemangiomatozis. BMJ Case Rep. 2014. https:\/\/doi.org\/10.1136\/bcr-2014-203746.","journal-title":"BMJ Case Rep"},{"issue":"6","key":"477_CR45","doi-asserted-by":"publisher","first-page":"e1589","DOI":"10.1542\/peds.2010-0077","volume":"126","author":"H Pavlakovic","year":"2010","unstructured":"Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126(6):e1589\u201393. https:\/\/doi.org\/10.1542\/peds.2010-0077.","journal-title":"Pediatrics"},{"issue":"1","key":"477_CR46","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/s41598-018-22787-8","volume":"8","author":"Y Ji","year":"2018","unstructured":"Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L, et al. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep. 2018;8(1):4264. https:\/\/doi.org\/10.1038\/s41598-018-22787-8.","journal-title":"Sci Rep"},{"issue":"2","key":"477_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1525-1470.2011.01345.x","volume":"28","author":"L Bagazgoitia","year":"2011","unstructured":"Bagazgoitia L, Torrelo A, Guti\u00e9rrez JC, Hern\u00e1ndez-Mart\u00edn A, Luna P, Guti\u00e9rrez M, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011;28(2):108\u201314. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01345.x.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"477_CR48","first-page":"16","volume":"82","author":"P McGee","year":"2013","unstructured":"McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16\u201320.","journal-title":"Ulster Med J"},{"issue":"6","key":"477_CR49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/pde.12686","volume":"32","author":"J Bernabeu-Wittel","year":"2015","unstructured":"Bernabeu-Wittel J, Narv\u00e1ez-Moreno B, de la Torre-Garc\u00eda JM, Fern\u00e1ndez-Pineda I, Dom\u00ednguez-Cruz JJ, Coserr\u00eda-S\u00e1nchez F, et al. Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol. Pediatr Dermatol. 2015;32(6):853\u20137. https:\/\/doi.org\/10.1111\/pde.12686.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"477_CR50","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1177\/000348941112001010","volume":"120","author":"MD Menezes","year":"2011","unstructured":"Menezes MD, McCarter R, Greene EA, Bauman NM. Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. Ann Otol Rhinol Laryngol. 2011;120(10):686\u201395. https:\/\/doi.org\/10.1177\/000348941112001010.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"477_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14484","author":"S Frost","year":"2020","unstructured":"Frost S, Saddi V, Teng A, Mallitt KA, Adams S, Williamson B, et al. Propranolol\u2019s effects on the sleep of infants with hemangiomas: a prospective pilot study. Pediatr Dermatol. 2020. https:\/\/doi.org\/10.1111\/pde.14484.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"477_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/ajd.12156","volume":"55","author":"K Gonski","year":"2014","unstructured":"Gonski K, Wargon O. Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children\u2019s Hospital. Australas J Dermatol. 2014;55(3):209\u201311. https:\/\/doi.org\/10.1111\/ajd.12156.","journal-title":"Australas J Dermatol"},{"issue":"10","key":"477_CR53","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1440-1754.2012.02521.x","volume":"48","author":"RJ Phillips","year":"2012","unstructured":"Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48(10):902\u20136. https:\/\/doi.org\/10.1111\/j.1440-1754.2012.02521.x.","journal-title":"J Paediatr Child Health"},{"issue":"6","key":"477_CR54","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/bjd.16334","volume":"178","author":"C Mahon","year":"2018","unstructured":"Mahon C, Heron G, Perkins D, Drage A, Wargon O. Oral propranolol for infantile haemangioma may be associated with transient gross motor delay. Br J Dermatol. 2018;178(6):1443\u20134. https:\/\/doi.org\/10.1111\/bjd.16334.","journal-title":"Br J Dermatol"},{"issue":"5","key":"477_CR55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/pde.13229","volume":"34","author":"N Gonz\u00e1lez-Llorente","year":"2017","unstructured":"Gonz\u00e1lez-Llorente N, Del Olmo-Benito I, Mu\u00f1oz-Ollero N, Descalzo MA, Garc\u00eda-Doval I, Torrelo A. Study of cognitive function in children treated with propranolol for infantile hemangioma. Pediatr Dermatol. 2017;34(5):554\u20138. https:\/\/doi.org\/10.1111\/pde.13229.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"477_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaad.2016.02.1218","volume":"75","author":"AV Moyakine","year":"2016","unstructured":"Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, van der Vleuten CJ. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016;75(1):59-63.e1. https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1218.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"477_CR57","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jaad.2015.04.053","volume":"73","author":"AV Moyakine","year":"2015","unstructured":"Moyakine AV, Hermans DJ, Fuijkschot J, van der Vleuten CJ. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development. J Am Acad Dermatol. 2015;73(2):341\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2015.04.053.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"477_CR58","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2014.01.905","volume":"70","author":"A \u00c1barz\u00faa-Araya","year":"2014","unstructured":"\u00c1barz\u00faa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol. 2014;70(6):1045\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2014.01.905.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"477_CR59","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2020.1788938","volume":"13","author":"SP Koh","year":"2020","unstructured":"Koh SP, Leadbitter P, Smithers F, Tan ST. \u03b2-Blocker therapy for infantile hemangioma. Expert Rev Clin Pharmacol. 2020;13(8):899\u2013915. https:\/\/doi.org\/10.1080\/17512433.2020.1788938.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"477_CR60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaad.2010.11.056","volume":"65","author":"MF Rapha\u00ebl","year":"2011","unstructured":"Rapha\u00ebl MF, de Graaf M, Breugem CC, Pasmans S, Breur J. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol. 2011;65(2):420\u20131. https:\/\/doi.org\/10.1016\/j.jaad.2010.11.056.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"477_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003908","volume":"95","author":"Y Ji","year":"2016","unstructured":"Ji Y, Wang Q, Chen S, Xiang B, Xu Z, Li Y, et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine (Baltimore). 2016;95(24): e3908. https:\/\/doi.org\/10.1097\/md.0000000000003908.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"477_CR62","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.bjps.2013.07.035","volume":"66","author":"M de Graaf","year":"2013","unstructured":"de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. J Plast Reconstr Aesthet Surg. 2013;66(12):1732\u201340. https:\/\/doi.org\/10.1016\/j.bjps.2013.07.035.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"4","key":"477_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/pde.13177","volume":"34","author":"CB Bayart","year":"2017","unstructured":"Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413\u201321. https:\/\/doi.org\/10.1111\/pde.13177.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"477_CR64","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/bjd.15317","volume":"176","author":"M Tasani","year":"2017","unstructured":"Tasani M, Glover M, Martinez AE, Shaw L. Atenolol treatment for infantile haemangioma. Br J Dermatol. 2017;176(5):1400\u20132. https:\/\/doi.org\/10.1111\/bjd.15317.","journal-title":"Br J Dermatol"},{"issue":"3","key":"477_CR65","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/jdv.14590","volume":"32","author":"A Alexopoulos","year":"2018","unstructured":"Alexopoulos A, Thanopoulou I, Dakoutrou M, Georgiadou E, Chrousos GP, Kakourou T. Atenolol treatment for severe infantile hemangiomas: a single-centre prospective study. J Eur Acad Dermatol Venereol. 2018;32(3):e117\u20139. https:\/\/doi.org\/10.1111\/jdv.14590.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"477_CR66","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1111\/jdv.15464","volume":"33","author":"M Dakoutrou","year":"2019","unstructured":"Dakoutrou M, Alexopoulos A, Miligkos M, Georgiadou E, Kanaka-Gantenbein C, Kakourou T. Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre. J Eur Acad Dermatol Venereol. 2019;33(5):e199\u2013200. https:\/\/doi.org\/10.1111\/jdv.15464.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"477_CR67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ad.2019.03.015","volume":"111","author":"X Calder\u00f3n-Castrat","year":"2020","unstructured":"Calder\u00f3n-Castrat X, Vel\u00e1squez F, Castro R, Ballona R. Oral atenolol for infantile hemangioma: case series of 46 infants. Actas Dermosifiliogr. 2020;111(1):59\u201362. https:\/\/doi.org\/10.1016\/j.ad.2019.03.015.","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"477_CR68","doi-asserted-by":"publisher","first-page":"116","DOI":"10.21037\/atm-20-5359","volume":"9","author":"ZL Zhao","year":"2021","unstructured":"Zhao ZL, Liu C, Wang QZ, Wu HW, Zheng JW. Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients. Ann Transl Med. 2021;9(2):116. https:\/\/doi.org\/10.21037\/atm-20-5359.","journal-title":"Ann Transl Med."},{"key":"477_CR69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2021.0454","author":"Y Ji","year":"2021","unstructured":"Ji Y, Chen S, Yang K, Zhang X, Zhou J, Li L, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021. https:\/\/doi.org\/10.1001\/jamaoto.2021.0454.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"477_CR70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnins.2019.00033","volume":"13","author":"C Laurens","year":"2019","unstructured":"Laurens C, Abot A, Delarue A, Knauf C. Central effects of beta-blockers may be due to nitric oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier. Front Neurosci. 2019;13:33. https:\/\/doi.org\/10.3389\/fnins.2019.00033.","journal-title":"Front Neurosci"},{"issue":"1","key":"477_CR71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2133.2012.11131.x","volume":"168","author":"E Pope","year":"2013","unstructured":"Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol. 2013;168(1):222\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11131.x.","journal-title":"Br J Dermatol"},{"key":"477_CR72","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1035","author":"E McGillis","year":"2020","unstructured":"McGillis E, Baumann T, LeRoy J. Death associated with nadolol for infantile hemangioma: a case for improving safety. Pediatrics. 2020. https:\/\/doi.org\/10.1542\/peds.2019-1035.","journal-title":"Pediatrics"},{"issue":"3","key":"477_CR73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0022-3476(68)80208-2","volume":"72","author":"NC Fost","year":"1968","unstructured":"Fost NC, Esterly NB. Successful treatment of juvenile hemangiomas with prednisone. J Pediatr. 1968;72(3):351\u20137. https:\/\/doi.org\/10.1016\/s0022-3476(68)80208-2.","journal-title":"J Pediatr"},{"issue":"3","key":"477_CR74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/PRS.0b013e31827c6fab","volume":"131","author":"A Izadpanah","year":"2013","unstructured":"Izadpanah A, Izadpanah A, Kanevsky J, Belzile E, Schwarz K. Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. Plast Reconstr Surg. 2013;131(3):601\u201313. https:\/\/doi.org\/10.1097\/PRS.0b013e31827c6fab.","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"477_CR75","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3896","volume":"137","author":"S Chinnadurai","year":"2016","unstructured":"Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, et al. Pharmacologic interventions for infantile hemangioma: a meta-analysis. Pediatrics. 2016;137(2): e20153896. https:\/\/doi.org\/10.1542\/peds.2015-3896.","journal-title":"Pediatrics"},{"issue":"11","key":"477_CR76","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00431-015-2561-1","volume":"174","author":"MM Aly","year":"2015","unstructured":"Aly MM, Hamza AF, Abdel Kader HM, Saafan HA, Ghazy MS, Ragab IA. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015;174(11):1503\u20139. https:\/\/doi.org\/10.1007\/s00431-015-2561-1.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"477_CR77","first-page":"9","volume":"8","author":"A Pandey","year":"2010","unstructured":"Pandey A, Gangopadhyay AN, Sharma SP, Kumar V, Gupta DK, Gopal SC. Evaluation of topical steroids in the treatment of superficial hemangioma. Skinmed. 2010;8(1):9\u201311.","journal-title":"Skinmed."},{"issue":"7","key":"477_CR78","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ijom.2018.03.024","volume":"47","author":"V Pandey","year":"2018","unstructured":"Pandey V, Tiwari P, Sharma SP, Kumar R, Singh OP. Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. Int J Oral Maxillofac Surg. 2018;47(7):908\u201312. https:\/\/doi.org\/10.1016\/j.ijom.2018.03.024.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"6","key":"477_CR79","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1111\/pde.12023","volume":"30","author":"S Kaylani","year":"2013","unstructured":"Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol. 2013;30(6):e194\u20137. https:\/\/doi.org\/10.1111\/pde.12023.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"477_CR80","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/028418602753669607","volume":"41","author":"J Perez","year":"2002","unstructured":"Perez J, Pardo J, Gomez C. Vincristine\u2014an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41(2):197\u20139. https:\/\/doi.org\/10.1080\/028418602753669607.","journal-title":"Acta Oncol"},{"issue":"2","key":"477_CR81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.arcped.2003.10.014","volume":"11","author":"O Enjolras","year":"2004","unstructured":"Enjolras O, Brevi\u00e8re GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr. 2004;11(2):99\u2013107. https:\/\/doi.org\/10.1016\/j.arcped.2003.10.014.","journal-title":"Arch Pediatr"},{"issue":"5","key":"477_CR82","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archdermatol.2010.67","volume":"146","author":"E Pope","year":"2010","unstructured":"Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol. 2010;146(5):564\u20135. https:\/\/doi.org\/10.1001\/archdermatol.2010.67.","journal-title":"Arch Dermatol"},{"issue":"6","key":"477_CR83","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1542\/peds.2012-3828","volume":"131","author":"H Chan","year":"2013","unstructured":"Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics. 2013;131(6):e1739\u201347. https:\/\/doi.org\/10.1542\/peds.2012-3828.","journal-title":"Pediatrics"},{"issue":"1","key":"477_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1525-1470.2011.01664.x","volume":"29","author":"A Chakkittakandiyil","year":"2012","unstructured":"Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried E, Lara-Corrales I, Lam J, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012;29(1):28\u201331. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01664.x.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"477_CR85","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2340\/00015555-2681","volume":"97","author":"M Khan","year":"2017","unstructured":"Khan M, Boyce A, Prieto-Merino D, Svensson \u00c5, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167\u201371. https:\/\/doi.org\/10.2340\/00015555-2681.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"477_CR86","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000369164","volume":"230","author":"L Hu","year":"2015","unstructured":"Hu L, Huang HZ, Li X, Lin XX, Li W. Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma. Dermatology. 2015;230(2):150\u20135. https:\/\/doi.org\/10.1159\/000369164.","journal-title":"Dermatology"},{"issue":"2","key":"477_CR87","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/pde.12767","volume":"33","author":"L Weibel","year":"2016","unstructured":"Weibel L, Barysch MJ, Scheer HS, K\u00f6nigs I, Neuhaus K, Schiestl C, et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol. 2016;33(2):184\u201390. https:\/\/doi.org\/10.1111\/pde.12767.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"477_CR88","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s00403-018-1815-y","volume":"310","author":"L Zheng","year":"2018","unstructured":"Zheng L, Li Y. Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. Arch Dermatol Res. 2018;310(4):261\u20139. https:\/\/doi.org\/10.1007\/s00403-018-1815-y.","journal-title":"Arch Dermatol Res"},{"key":"477_CR89","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0596","author":"FZ Mu\u00f1oz-Garza","year":"2021","unstructured":"Mu\u00f1oz-Garza FZ, R\u00edos M, Ro\u00e9-Crespo E, Bernabeu-Wittel J, Montserrat-Garc\u00eda MT, Puig L, et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: a randomized clinical trial. JAMA Dermatol. 2021. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0596.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"477_CR90","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1111\/bjd.15865","volume":"178","author":"J Borok","year":"2018","unstructured":"Borok J, Gangar P, Admani S, Proudfoot J, Friedlander SF. Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial. Br J Dermatol. 2018;178(1):e51\u20132. https:\/\/doi.org\/10.1111\/bjd.15865.","journal-title":"Br J Dermatol"},{"issue":"3","key":"477_CR91","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2019.02.029","volume":"82","author":"BA Drolet","year":"2020","unstructured":"Drolet BA, Boakye-Agyeman F, Harper B, Holland K, Lewandowski A, Stefanko N, et al. Systemic timolol exposure following topical application to infantile hemangiomas. J Am Acad Dermatol. 2020;82(3):733\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.029.","journal-title":"J Am Acad Dermatol"},{"key":"477_CR92","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-0355","author":"K P\u00fcttgen","year":"2016","unstructured":"P\u00fcttgen K, Lucky A, Adams D, Pope E, McCuaig C, Powell J, et al. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2016-0355.","journal-title":"Pediatrics"},{"issue":"1","key":"477_CR93","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1023\/a:1017962731813","volume":"103","author":"AH Shedden","year":"2001","unstructured":"Shedden AH, Laurence J, Barrish A, Olah TV. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol. 2001;103(1):73\u20139. https:\/\/doi.org\/10.1023\/a:1017962731813.","journal-title":"Doc Ophthalmol"},{"issue":"7","key":"477_CR94","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00431-015-2570-0","volume":"174","author":"PH Hoeger","year":"2015","unstructured":"Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Atti MCD, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855\u201365. https:\/\/doi.org\/10.1007\/s00431-015-2570-0.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"477_CR95","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/pde.13407","volume":"35","author":"R Dalla Costa","year":"2018","unstructured":"Dalla Costa R, Prindaville B, Wiss K. Doing the math: a simple approach to topical timolol dosing for infantile hemangiomas. Pediatr Dermatol. 2018;35(2):276\u20137. https:\/\/doi.org\/10.1111\/pde.13407.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"477_CR96","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/pde.13816","volume":"36","author":"DB Mannschreck","year":"2019","unstructured":"Mannschreck DB, Huang AH, Lie E, Psoter K, Puttgen K. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2019;36(3):283\u20139. https:\/\/doi.org\/10.1111\/pde.13816.","journal-title":"Pediatr Dermatol"},{"key":"477_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.554847","volume":"11","author":"J Qiao","year":"2020","unstructured":"Qiao J, Lin J, Zhang D, Li J, Chen C, Yu H, et al. Efficacy of combined topical timolol and oral propranolol for treating infantile hemangioma: a meta-analysis of randomized controlled trials. Front Pharmacol. 2020;11: 554847. https:\/\/doi.org\/10.3389\/fphar.2020.554847.","journal-title":"Front Pharmacol"},{"issue":"2","key":"477_CR98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1525-1470.2008.00857.x","volume":"26","author":"CC McCuaig","year":"2009","unstructured":"McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol. 2009;26(2):203\u201312. https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00857.x.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"477_CR99","doi-asserted-by":"publisher","first-page":"733e","DOI":"10.1097\/PRS.0b013e318245e739","volume":"129","author":"PK Thayal","year":"2012","unstructured":"Thayal PK, Bhandari PS, Sarin YK. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg. 2012;129(4):733e-e735. https:\/\/doi.org\/10.1097\/PRS.0b013e318245e739.","journal-title":"Plast Reconstr Surg"},{"issue":"12","key":"477_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/0003489418802288","volume":"127","author":"MR Kinzinger","year":"2018","unstructured":"Kinzinger MR, Strong EB, Bernard J, Steele TO. Intralesional bevacizumab for the treatment of recurrent sinonasal hemangioma. Ann Otol Rhinol Laryngol. 2018;127(12):969\u201373. https:\/\/doi.org\/10.1177\/0003489418802288.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"3","key":"477_CR101","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/09546634.2019.1590521","volume":"31","author":"HH Sabry","year":"2020","unstructured":"Sabry HH, Sorour NE, Akl EM. Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma. J Dermatol Treat. 2020;31(3):279\u201384. https:\/\/doi.org\/10.1080\/09546634.2019.1590521.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"477_CR102","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/lsm.22455","volume":"48","author":"S Chinnadurai","year":"2016","unstructured":"Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: a systematic review. Lasers Surg Med. 2016;48(3):221\u201333. https:\/\/doi.org\/10.1002\/lsm.22455.","journal-title":"Lasers Surg Med"},{"issue":"7","key":"477_CR103","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/lsm.23205","volume":"52","author":"C Chelleri","year":"2020","unstructured":"Chelleri C, Monzani NA, Gelmetti C, Milani GP, Fossali EF, Galeone C, et al. Residual lesions after pharmacological and dye-laser treatment of infantile hemangiomas: critical review of 432 cases. Lasers Surg Med. 2020;52(7):597\u2013603. https:\/\/doi.org\/10.1002\/lsm.23205.","journal-title":"Lasers Surg Med"},{"issue":"5","key":"477_CR104","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/1203475418770570","volume":"22","author":"JY Wang","year":"2018","unstructured":"Wang JY, Ighani A, Ayala AP, Akita S, Lara-Corrales I, Alavi A. Medical, surgical, and wound care management of ulcerated infantile hemangiomas: a systematic review [formula: see text]. J Cutan Med Surg. 2018;22(5):495\u2013504. https:\/\/doi.org\/10.1177\/1203475418770570.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"477_CR105","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1525-1470.2012.01879.x","volume":"30","author":"D Metry","year":"2013","unstructured":"Metry D, Frieden IJ, Hess C, Siegel D, Maheshwari M, Baselga E, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. 2013;30(1):71\u201389. https:\/\/doi.org\/10.1111\/j.1525-1470.2012.01879.x.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"477_CR106","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2310\/7750.2012.12037","volume":"17","author":"CC McCuaig","year":"2013","unstructured":"McCuaig CC, Cohen L, Powell J, Hatami A, Marcoux D, Maari C, et al. Therapy of ulcerated hemangiomas. J Cutan Med Surg. 2013;17(4):233\u201342. https:\/\/doi.org\/10.2310\/7750.2012.12037.","journal-title":"J Cutan Med Surg"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00477-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00477-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T16:30:19Z","timestamp":1641486619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00477-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00477-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"4 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julie Powell: Advisory board and speaker: Pierre-Fabre Dermatology, Pfizer, Sanofi-Genzyme, Novartis. Caroline Colmant: no conflicts to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish identifying photos was obtained from the patients\/parents.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Both authors contributed to the writing and revision of this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}